Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

Strategies for Managing Treatment-Naïve CLL with High-Risk Features

Videos

Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from clinical trials.

Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA

Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.

Catherine Coombs, MD discusses the present CLL front-line treatment landscape.

Current Front-Line Treatment Options for CLL in 2023

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

Javier Pinilla-Ibarz, MD, PhD, senior member, head of Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia (CLL).

Although second-generation BTK inhibitors generally elicit more durable responses, all BTK inhibitors, such as acalabrutinib (Calquence) and zanubrutinib (Brukinsa), have class effects, including bleeding and hypertension, Pinilla-Ibarz says. While the possibility for cardiovascular effects may make these second-generation BTK inhibitors seem suboptimal for certain high-risk patients, other drugs being investigated in CLL may still cause similar adverse effects (AEs) in longer follow-up, Pinilla-Ibarz notes.

Since AEs are a possibility with all BTK inhibitors, even well tolerated ones such as ibrutinib (Imbruvica), closely monitoring patients throughout treatment is important, Pinilla-Ibarz explains. Fortunately, patients with CLL have a variety of treatment options, and alternatives exist for those who respond poorly to certain agents, Pinilla-Ibarz concludes.

Javier Pinilla-Ibarz, MD, PhD, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia.

Dr. Pinilla-Ibarz on Choosing Second-line BTK Inhibitors in CLL

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses the outcomes of patients with high-risk chronic lymphocytic leukemia (CLL) and how ibrutinib (Imbruvica) targets these patients.

High-risk patients with CLL has always been a challenge for patients being treated with chemoimmunotherapy, as they present with molecular features such as 

. These patients don't respond very well to standard chemoimmunotherapy regimens.

However, with the introduction of new BCR inhibitors such as ibrutinib and idelalisib (Zydelig), patients are able to be successfully treated and can experience an improvement in progression-free survival.

Javier Pinilla, MD, PhD

Articles

Strategies for Managing Treatment-Naïve CLL with High-Risk Features

Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA

Current Front-Line Treatment Options for CLL in 2023

Dr. Pinilla-Ibarz on Choosing Second-line BTK Inhibitors in CLL

Dr. Pinilla-Ibarz on Ibrutinib's Efficacy in Treating High-Risk Patients With CLL